EVOSCIENCES LEASING GmbH

Vielen Dank für Euren Besuch!

𝐌𝐢𝐭 𝐝𝐞𝐦 𝐧𝐞𝐮𝐞𝐧 𝐓𝐫𝐢𝐩𝐥𝐞𝐪𝐮𝐚𝐝 𝐋𝐂-𝐌𝐒 CUP Laboratorien Dr. Freitag GmbH 𝐀𝐫𝐳𝐧𝐞𝐢𝐦𝐢𝐭𝐭𝐞𝐥𝐬𝐢𝐜𝐡𝐞𝐫𝐡𝐞𝐢𝐭 𝐚𝐮𝐟 𝐡ö𝐜𝐡𝐬𝐭𝐞𝐦 𝐍𝐢𝐯𝐞𝐚𝐮 💡 Nachweis winziger Spuren toxischer Analyten und beispiellose Präzision bei der Arzneimittelsicherheit. 🚀 EVOSCIENCES LEASING GmbH, Dirk Freitag-Stechl, Marc Wiesmann, Thermo Scientific, Guido Sonsmann, Szotek Susanne, Kristina Hempel, PhD, Dr. Sylke Wulf, Albert Hermann, Dr. Elisa Lehnert, Michael Woywod, Martin Kaltenecker

If you are looking for cost-effective, complete laboratory solutions and how to finance your lab and production space, meet and talk to LSCN GmbH partners. Manuela Habeker, Jérôme Lutz, Dr. Stephan Binder and Alrik Koppenhoefer will be at analytica. Meet us during GoingPublic Media AG's Finance Days on 10. & 11. April 2024 in hall A3, booth 529-3.

Achtung Start Up - nicht versäumen! analytica Finance Days am 10.4 und 11.4!

𝐋𝐞𝐚𝐬𝐢𝐧𝐠 𝐯𝐨𝐧 𝐋𝐚𝐛𝐨𝐫𝐠𝐞𝐫ä𝐭𝐞𝐧 𝐟ü𝐫 𝐒𝐭𝐚𝐫𝐭 𝐔𝐩 𝐮𝐧𝐝 𝐣𝐮𝐧𝐠𝐞 𝐔𝐧𝐭𝐞𝐫𝐧𝐞𝐡𝐦𝐞𝐧 𝐦𝐢𝐭 𝐮𝐧𝐬𝐞𝐫𝐞𝐦 "𝐒𝐭𝐚𝐫𝐭 𝐔𝐩 𝐏𝐫𝐨𝐠𝐫𝐚𝐦𝐦" 🚀 🚀 𝗪𝗶𝗿 𝘂𝗻𝘁𝗲𝗿𝘀𝘁ü𝘁𝘇𝗲𝗻 𝘃𝗼𝗻 𝗱𝗲𝗿 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗲𝗹𝗹𝗲𝗻 𝗔𝘂𝗳𝗮𝗿𝗯𝗲𝗶𝘁𝘂𝗻𝗴 𝗱𝗲𝗿 𝗙𝗶𝗻𝗮𝗻𝘇𝘂𝗻𝘁𝗲𝗿𝗹𝗮𝗴𝗲𝗻 𝗯𝗶𝘀 𝗵𝗶𝗻 𝘇𝘂𝗿 𝗚𝗲𝗻𝗲𝗵𝗺𝗶𝗴𝘂𝗻𝗴 𝗲𝗶𝗻𝗲𝗿 𝗞𝗿𝗲𝗱𝗶𝘁𝗹𝗶𝗻𝗶𝗲. Evolve Partners - Biofin Consulting GmbH, Alrik Koppenhoefer, Holger Bengs, Dr. Stephan Binder, Jérôme Lutz, Uwe Jacobs, Tim Tiedemann, Christine Uekert, EVOSCIENCES SAS, Ludwig Kubacki, LSCN GmbH #leasing, #Laborgeräte, #StartUp, #Laborgeräteleasing, #Biotech, #Bioleasing, #Absatzfinanzierung,

𝐋𝐞𝐚𝐬𝐢𝐧𝐠 𝐯𝐨𝐧 𝐋𝐚𝐛𝐨𝐫𝐠𝐞𝐫ä𝐭𝐞𝐧 𝐟ü𝐫 𝐒𝐭𝐚𝐫𝐭 𝐔𝐩 𝐮𝐧𝐝 𝐣𝐮𝐧𝐠𝐞 𝐔𝐧𝐭𝐞𝐫𝐧𝐞𝐡𝐦𝐞𝐧 𝐦𝐢𝐭 𝐮𝐧𝐬𝐞𝐫𝐞𝐦 "𝐒𝐭𝐚𝐫𝐭 𝐔𝐩 𝐏𝐫𝐨𝐠𝐫𝐚𝐦𝐦" 🚀 🚀 𝗪𝗶𝗿 𝘂𝗻𝘁𝗲𝗿𝘀𝘁ü𝘁𝘇𝗲𝗻 𝘃𝗼𝗻 𝗱𝗲𝗿 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗲𝗹𝗹𝗲𝗻 𝗔𝘂𝗳𝗮𝗿𝗯𝗲𝗶𝘁𝘂𝗻𝗴 𝗱𝗲𝗿 𝗙𝗶𝗻𝗮𝗻𝘇𝘂𝗻𝘁𝗲𝗿𝗹𝗮𝗴𝗲𝗻 𝗯𝗶𝘀 𝗵𝗶𝗻 𝘇𝘂𝗿 𝗚𝗲𝗻𝗲𝗵𝗺𝗶𝗴𝘂𝗻𝗴 𝗲𝗶𝗻𝗲𝗿 𝗞𝗿𝗲𝗱𝗶𝘁𝗹𝗶𝗻𝗶𝗲. Evolve Partners - Biofin Consulting GmbH, Alrik Koppenhoefer, Holger Bengs, Dr. Stephan Binder, Jérôme Lutz, Uwe Jacobs, Tim Tiedemann, Christine Uekert, EVOSCIENCES SAS, Ludwig Kubacki, LSCN GmbH #leasing, #Laborgeräte, #StartUp, #Laborgeräteleasing, #Biotech, #Bioleasing, #Absatzfinanzierung,

Don´t miss this KPMG Life Sciences Event!

Great success for you Laura Gertenbach!

🌟 Excited to share groundbreaking collaboration news with Flomics 🇪🇸 thanks to the EVOSCIENCES SAS Biotech Program (https://lnkd.in/e7NfHieS). In an exciting development for cancer diagnostics, Flomics has teamed up with EVOSCIENCES SAS, leveraging cutting-edge technology through the acquisition of Illumina's NextSeq 2000 DNA sequencer. This collaboration marks a significant milestone in the fight against cancer, combining Flomics' innovative approach to cancer detection with state-of-the-art sequencing technology. Flomics specializes in a groundbreaking multicancer blood test that utilizes changes in the expression patterns of RNA molecules circulating in the blood to detect and screen for cancer before the first symptoms appear. This test is a game-changer for early-stage screening programs, especially for individuals at high risk of developing cancer. By identifying these changes early, Flomics' test can significantly improve the chances of successful treatment and survival. Flomics is pioneering in the field of liquid biopsies, specifically focusing on multicancer blood test. "This test is designed to detect changes in the expression patterns of RNA molecules circulating in the blood, enabling us to identify and screen for cancer even before the first symptoms arise. Our approach is particularly suited for early-stage screening programs aimed at individuals at risk" says João Curado. The science behind Flomics work lies in the study of circulating molecules present in blood, a rapidly evolving area over the past decade. Blood serves not only as a carrier of various cell types but also as a medium for cell-free RNA (cfRNA). Since all organs release RNA into the circulation, liquid biopsies offer a comprehensive snapshot of an individual's health from a single blood draw. This partnership not only demonstrates the potential of combining innovative biotechnical approaches with cutting-edge technology but also highlights the importance of collaboration in advancing medical science. By working together, Flomics and EVOSCIENCES SAS are paving the way for significant improvements in cancer diagnostics, making early detection more accessible and effective than ever before. Thank you to João Curado for his trust and Rubén Melgarejo Ibáñez for the pleasant collaboration, Want to learn more about Next-generation liquid biopsy ? go to https://www.flomics.com/ #InnovationInHealthcare #LiquidBiopsies #CancerDetection #Collaboration #Flomics #Evosciences #NextGenerationSequencing

Glückwunsch den Gewinnern! 🚀